ESR1 and breast neoplasm: Indeed, such effects have been actually linked via clinical and pathological features to breast tumors of the Luminal B subtype (or related: ER+, PR- and HER2-) giving rise to basal-like and endocrine resistant phenotypes (Liu et al., 2018).